Results 221 to 230 of about 378,238 (343)

Interventional oncology in children: Where are we now?

Journal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel, Fernando Gómez Muñoz   +1 more
wiley   +1 more source

HIV-associated lymphoproliferative disorders: Single-center experience. [PDF]

Medicine (Baltimore)
Demirtas D, Toptas T, Yilmaz AF, Erturk Sengel B, Yuksel T, Kokkaya YE, Candan O, Yanik AM, Salim S, Ulukoylu Menguc M, Arikan F, Atagunduz I, Korten V, Tuglular AT.   +13 more
europepmc   +1 more source

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

Cancer Immunology and Immunotherapy, 2007
F. Ghiringhelli, C. Ménard, P. Puig, S. Ladoire, S. Roux, F. Martin, E. Solary, A. Le Cesne, L. Zitvogel, B. Chauffert   +9 more
semanticscholar   +1 more source

Clinical Characteristics and Outcomes of Neural Epidermal Growth Factor-like 1 Protein-Associated Membranous Nephropathy

Kidney International Reports
Suruthy Narayanasami, Niranjan Anitha Vijayakumar, Mayuri Trivedi, Aravind Sekar, Shabna Sulaiman, Saurabh Nayak, Neeraj Inamdar, Sourabh Sharma, Rajeevalochana Parthasarathy, Vidya Kadam, Vaibhav Keskar, Sahil Bagai, Ashwani Kumar, Bajinder Reen, Anila Abraham Kurien, Alok Sharma, Dinesh Khullar, Benil Hafeeq, Arvind Krishnakumar, Shafeeque Rahman KV, Ismail NA, Sanjeev Nair, Smita Divyaveer, Manish Rathi, Harbir Singh Kohli, Ritambhra Nada, Raja Ramachandran   +26 more
doaj   +1 more source

Imaging of Abdominal Complications in Children With Acute Lymphoblastic Leukaemia

Journal of Medical Imaging and Radiation Oncology, EarlyView.
ABSTRACT Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy and remains one of the most common causes of cancer‐related death in children and adolescents. Five‐year overall survival rates now exceed 90% with current multidrug chemotherapeutic regimens. This improvement, coupled with the toxicity of chemotherapy, has led to the
Luke R. Holmes, Rishi S. Kotecha, Derek J. Roebuck   +2 more
wiley   +1 more source

Comparison of Rituximab and Cyclophosphamide for Induction Therapy in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: A Systematic Review of Randomized Trials and Comparative Cohort Evidence. [PDF]

Cureus
Khan SH, Manzoor MZ, Khan J.
europepmc   +1 more source

Personalized Cancer Vaccines in the Clinical Trial Pipeline

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study analyzes the current landscape of personalized cancer vaccine clinical trials, highlighting trends in vaccine platforms, trial phases, and geographic distribution. Peptide and dendritic cell vaccines dominate early‐stage research, with promising immune responses observed in melanoma, glioblastoma, and urothelial cancer trials.
Liudmila Iamukova, Elena Alferova
wiley   +1 more source

Superiority of high-dose cytarabine-based mobilisation over cyclophosphamide or plerixafor in primary CNS lymphoma. [PDF]

Ann Hematol
Li Q, Zhu L, Ma Y, Ma J, Zhang M, Lin Z, Chen B.   +6 more
europepmc   +1 more source

Managing Skin Side Effects Associated With Oncology Treatments: Asian Perspective on Use of Dermocosmetics

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Skin adverse events (AEs) frequently accompany all types of anticancer treatments. This publication discusses how recent international guidance on best‐practices use of dermocosmetics can be adapted to the North Asia region (China, Hong Kong, Japan, Republic of Korea, and Taiwan).
Meng Pan, Jianguo Sun, Makoto Kawashima, You Chan Kim, Mison Chun, Chia‐Yu Chu, Yi‐Hsin Liang, Mee Chang, Delphine Kerob, Brigitte Dreno   +9 more
wiley   +1 more source

Cyclophosphamide for the Treatment of Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome Following CD19-Targeted CAR T-Cell Therapy. [PDF]

J Med Cases
Frisch A, Marino L, Alsaadi D, Kasarabada A, Hua G, Ajebo G, Medlin S, Gul Z.   +7 more
europepmc   +1 more source